Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Robert Gray Biography and Net Worth

Director of enVVeno Medical

Mr. Gray had a 20-year career at Highmark, Inc., one of America's largest health insurance organizations, which serves over 20 million subscribers, and includes Highmark Blue Cross Blue Shield Pennsylvania, Highmark Blue Cross Blue Shield Delaware, and Highmark Blue Cross Blue Shield West Virginia. While at Highmark, Mr. Gray helped increase revenues to $12.3 billion from $6.9 billion, and helped generate an operating gain of $375 million from an operating loss of $91 million. In addition to being the Board Chairman, CEO, and President of several of Highmark's subsidiaries and affiliated companies, Mr. Gray was the Chief Financial Officer of Highmark's parent company and was the primary contact to Highmark's board of directors for Highmark's audit, investment and compensation (incentive plans) committees. His many responsibilities at Highmark included rate setting and reimbursement negotiations. Following Highmark, Mr. Gray co-founded U.S. Holdings LLC. (U.S. Implants LLC.), a national distributor of orthopedic implants. Mr. Gray engaged in Postgraduate Studies at the University of North Carolina-Chapel Hill and has an undergraduate degree from Bucknell University.

What is Robert Gray's net worth?: The estimated net worth of Robert Gray is at least $16,883.16 as of June 16th, 2021. Mr. Gray owns 5,572 shares of enVVeno Medical stock worth more than $16,883 as of December 30th. This net worth approximation does not reflect any other investments that Mr. Gray may own. Learn More about Robert Gray's net worth.
How do I contact Robert Gray?: The corporate mailing address for Mr. Gray and other enVVeno Medical executives is 70 DOPPLER, IRVINE CA, 92618. enVVeno Medical can also be reached via phone at (949) 261-2900 and via email at [email protected]. Learn More on Robert Gray's contact information.
Has Robert Gray been buying or selling shares of enVVeno Medical?: Robert Gray has not been actively trading shares of enVVeno Medical over the course of the past ninety days. Most recently, on Wednesday, June 16th, Robert Gray bought 2,000 shares of enVVeno Medical stock. The stock was acquired at an average cost of $6.25 per share, with a total value of $12,500.00. Following the completion of the transaction, the director now directly owns 5,572 shares of the company's stock, valued at $34,825. Learn More on Robert Gray's trading history.
Who are enVVeno Medical's active insiders?: enVVeno Medical's insider roster includes Robert Berman (CEO), Francis Duhay (Director), Marc Glickman (SVP), Robert Gray (Director), and Matthew Jenusaitis (Director). Learn More on enVVeno Medical's active insiders.
Are insiders buying or selling shares of enVVeno Medical?: In the last year, enVVeno Medical insiders bought shares 2 times. They purchased a total of 15,020 shares worth more than $39,998.60. In the last year, insiders at the sold shares 1 times. They sold a total of 8,334 shares worth more than $51,837.48. The most recent insider tranaction occured on December, 24th when Director Sanjay Shrivastava bought 5,400 shares worth more than $15,660.00. Insiders at enVVeno Medical own 16.0% of the company. Learn More about insider trades at enVVeno Medical.
Information on this page was last updated on 12/24/2024.

Robert Gray Insider Trading History at enVVeno Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/16/2021	Buy	2,000	$6.25	$12,500.00	5,572

Robert Gray Buying and Selling Activity at enVVeno Medical

enVVeno Medical Company Overview

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Today's Range

Now: $3.03

$3.03

$3.21

50 Day Range

MA: $3.19

$2.49

$3.65

2 Week Range

Now: $3.03

$2.45

$6.97

Volume

135,346 shs

Average Volume

115,083 shs

Market Capitalization

$53.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22